Cellbox Solutions, EUR 5M Series A final close
A paper co-authored by staff of Cellbox Solutions and researchers at the Fraunhofer IZI in Leipzig, dated January 2026 and published on the company's site, reports that shipping NK cells alive delivered 2.5 times more functional cells after recovery than cryopreservation. It tested three batches over about 44 hours of transport in a portable CO2 incubator. On 20 October 2026 the Cologne company announced the final close of its Series A at €5 million in total.
The first close, of approximately €3.5 million, was announced on 5 March 2026 and led by Companisto, a digital business angel network, together with existing investors including NRW.BANK. The remainder is approximately €1.5 million (our arithmetic: €5 million minus €3.5 million). According to the company, the new investors include members of Baltic Business Angels Invest GmbH, a Canadian family office and an undisclosed investor with pharmaceutical logistics experience. Existing investors NRW.BANK and Fraunhofer Venture also participated in the financing; the release does not say in which closing, and it gives no amounts per investor.
Who gave the money: business angels (Companisto's network led the first close), a family office and two existing investors. NRW.BANK describes itself as the development bank for North Rhine-Westphalia, acting on behalf of the state. Fraunhofer Venture is the spin-off unit of the Fraunhofer-Gesellschaft and lists Cellbox Solutions among its spin-outs. The company's site also says its product is supported by a European EIC - European Innovation Council grant; the amount is not published.
What the money pays for: according to the company, a wider offer built around its incubators, including rental and recurring services such as monitoring, fleet management and shipment coordination, and more partnerships with logistics providers in Europe, Asia and North America. It reports more than 400 systems on the market.
The limits: the 2.5 times figure comes from one study of one cell type by a team that includes company staff. No valuation and no per-investor amounts are published.